06/11/2001
London, UK – 6 November 2001: ReGen Therapeutics Plc (the “Company”), a company developing a potential treatment for Alzheimer’s disease, announces that it has today received notification that each of the following Directors have today subscribed for and acquired pursuant to the placing announced on 11 October 2001, the number of new ordinary shares set out against their respective names at 10p per new ordinary share:
Percy Lomax, Chairman, – 100,000 ordinary shares
Michael Harvey, Chief Executive Officer, – 30,000 ordinary shares
Malcolm Beveridge, non-executive deputy chairman – 100,000 ordinary shares
Keith Corbin, non-executive director – 70,000 ordinary shares
The Company has also today received notification that Norman Lott, the Finance Director, subscribed for and acquired on 2 November 2001 pursuant to the fundraising announced on 2 November 2001, 20,000 new ordinary shares at 10p per new ordinary share.
For further information, please contact:
BUCHANAN COMMUNICATIONS
Lisa Baderoon
lisab@buchanan.uk.com
Tel No: 020 7466 5000
M: 07721 413496